secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2021-09-17T23:59:59+00:00
Accession:  0001193125-21-275680
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

EVP and Chief of Business Operations Christopher Pierce resigns effective Sept 30, 2021
--------------------------------------------------------------------------------

- Christopher Pierce resigns as EVP and Chief of Business Operations, effective Sept 30, 2021.
- Resignation is to pursue another employment opportunity.
- No replacement named in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000119312521275680/0001193125-21-275680-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000119312521275680/d198573d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-275680

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer